Nektar Therapeutics (NKTR) Posts Q3 Loss of $0.21, Sales Top Expectations
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $70.36 -3.51%
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.21), $0.16 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $27.1 million versus the consensus estimate of $15.43 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- PepsiCo (PEP) Misses Q2 EPS by 1c, Beats on Revenue
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
